Overcoming the challenges of phytochemicals in triple negative breast cancer therapy : the path forward

dc.contributor.authorAlaouna, Mohammed
dc.contributor.authorPenny, Clement
dc.contributor.authorHull, Rodney
dc.contributor.authorMolefi, Thulo
dc.contributor.authorChauke-Malinga, Nkhensani
dc.contributor.authorKhanyile, Richard
dc.contributor.authorMakgoka, Malose
dc.contributor.authorBida, Meshack
dc.contributor.authorDlamini, Zodwa
dc.contributor.emailzodwa.dlamini@up.ac.zaen_US
dc.date.accessioned2024-09-13T13:05:09Z
dc.date.available2024-09-13T13:05:09Z
dc.date.issued2023-06-16
dc.description.abstractTriple negative breast cancer (TNBC) is a very aggressive subtype of breast cancer that lacks estrogen, progesterone, and HER2 receptor expression. TNBC is thought to be produced by Wnt, Notch, TGF-beta, and VEGF pathway activation, which leads to cell invasion and metastasis. To address this, the use of phytochemicals as a therapeutic option for TNBC has been researched. Plants contain natural compounds known as phytochemicals. Curcumin, resveratrol, and EGCG are phytochemicals that have been found to inhibit the pathways that cause TNBC, but their limited bioavailability and lack of clinical evidence for their use as single therapies pose challenges to the use of these phytochemical therapies. More research is required to better understand the role of phytochemicals in TNBC therapy, or to advance the development of more effective delivery mechanisms for these phytochemicals to the site where they are required. This review will discuss the promise shown by phytochemicals as a treatment option for TNBC.en_US
dc.description.departmentAnatomical Pathologyen_US
dc.description.departmentMedical Microbiologyen_US
dc.description.departmentSurgeryen_US
dc.description.librarianam2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipThe South African Medical Research Council (SAMRC) and the National Research Foundation (NRF).en_US
dc.description.urihttps://www.mdpi.com/journal/plantsen_US
dc.identifier.citationAlaouna, M.; Penny, C.; Hull, R.; Molefi, T.; Chauke-Malinga, N.; Khanyile, R.; Makgoka, M.; Bida, M.; Dlamini, Z. Overcoming the Challenges of Phytochemicals in Triple Negative Breast Cancer Therapy: The Path Forward. Plants 2023, 12, 2350. https://DOI.org/10.3390/plants12122350.en_US
dc.identifier.issn2223-7747 (online)
dc.identifier.other10.3390/plants12122350
dc.identifier.urihttp://hdl.handle.net/2263/98226
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en_US
dc.subjectPhytomedicineen_US
dc.subjectTyrosine kinaseen_US
dc.subjectWnten_US
dc.subjectEpithelial to mesenchymal transitionen_US
dc.subjectAngiogenesisen_US
dc.subjectMetastasisen_US
dc.subjectApoptosisen_US
dc.subjectTriple negative breast cancer (TNBC)en_US
dc.subjectBreast canceren_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleOvercoming the challenges of phytochemicals in triple negative breast cancer therapy : the path forwarden_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Alaouna_Overcoming_2023.pdf
Size:
2.38 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: